BLSM Latest Press Releases

-- November 12, 2026 --

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 4:01 PM

-- November 9, 2026 --

BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Globe Newswire 7:00 AM

-- November 4, 2026 --

BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting Globe Newswire 7:00 AM

-- November 3, 2026 --

BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference Globe Newswire 7:00 AM

-- October 22, 2026 --

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer Globe Newswire 7:00 AM

-- September 28, 2026 --

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer Globe Newswire 7:00 AM

-- September 18, 2026 --

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results Globe Newswire 7:00 AM

-- September 15, 2026 --

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer Globe Newswire 7:00 AM

-- September 3, 2026 --

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 7:00 AM

-- September 1, 2026 --

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer Globe Newswire 7:00 AM

-- August 18, 2026 --

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes